Study guide
3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes
Key Takeaways Explain This Topic AI
Glycemic targets in pregnancy are fasting below 95 mg/dL, 1-hour postprandial below 140 mg/dL, and 2-hour postprandial below 120 mg/dL.
Carbohydrate intake must remain at or above 175 g daily to prevent maternal ketosis, with carbohydrates supplying 35 to 45 percent of calories and breakfast carrying the lowest carbohydrate load.
Insulin is first-line pharmacotherapy because it does not cross the placenta in significant amounts, starting at 0.7 to 1.0 units per kg of current weight per day depending on gestational age.
Metformin and glyburide both cross the placenta, and glyburide is not recommended first-line because of higher rates of macrosomia and neonatal hypoglycemia.
Diet-controlled A1 gestational diabetes is delivered at 39 0/7 to 40 6/7 weeks, while medication-controlled A2 disease begins antenatal testing at 32 to 36 weeks and is delivered at 39 0/7 to 39 6/7 weeks.
Last updated: September 2026
Glycemic Control Targets & Management
Once GDM is diagnosed, the patient initiates daily blood glucose self-monitoring and lifestyle modifications. Standard capillary fingerstick monitoring is performed four times daily : upon waking (fasting) and 1 or 2 hours after the start of each major meal (breakfast, lunch, and dinner).
- Target Blood Glucose Thresholds (ACOG & ADA)
- Fasting: <95 mg/dL (5.3 mmol/L)
- 1-Hour Postprandial: <140 mg/dL (7.8 mmol/L)
- 2-Hour Postprandial: <120 mg/dL (6.7 mmol/L)
Mean 24-hour Glucose: ~100 mg/dL; target HbA1c in pregnancy is <6.0% (if attainable without severe hypoglycemia).
Medical Nutrition Therapy (MNT)
Medical Nutrition Therapy tailored by a registered dietitian is the foundation of management for all patients with GDM (A1GDM):
Caloric Allocation: Based on pre-pregnancy BMI:
- Normal weight (BMI 18.5–24.9): 30 kcal/kg/day
- Overweight (BMI 25.0–29.9): 22–25 kcal/kg/day
Obese (BMI ≥30): 22–25 kcal/kg/day (a moderate caloric reduction of ~30% reduces hyperglycemia without inducing maternal ketonemia).
Minimum carbohydrate intake: ≥175 g/day to prevent maternal ketosis, which is potentially neurotoxic to the developing fetal brain.
Macronutrient Composition:
Carbohydrates: 35% to 45% of total daily calories, emphasizing complex, low-glycemic-index carbohydrates with abundant dietary fiber (≥28 g/day).
Protein: 20% to 25% of daily calories.
Fats: 30% to 40% of daily calories, predominantly monounsaturated and polyunsaturated fatty acids.
Meal Distribution: Three moderate meals and two to three snacks daily. The morning breakfast meal should contain the lowest carbohydrate proportion (e.g., 15–30 grams) because morning cortisol and hPL levels peak, causing pronounced morning insulin resistance.
Physical Activity: Moderate aerobic exercise for 30 minutes, 5 days per week, or 10- to 15-minute brisk walks after each meal significantly improves skeletal muscle glucose uptake and blunts postprandial glucose surges.
Pharmacologic Management (A2GDM)
Pharmacotherapy is indicated when Medical Nutrition Therapy fails to maintain euglycemia—specifically when ≥10% to 20% of capillary blood glucose values exceed target thresholds within a 1- to 2-week monitoring interval, or when ultrasound demonstrates accelerated fetal abdominal circumference (>75th percentile).
1. Insulin (First-Line Gold Standard)
Insulin is the primary, preferred pharmacologic therapy endorsed by ACOG, ADA, and SMFM because it does not cross the placenta in significant amounts and provides precise dose titration.
Regimens: Typically combines intermediate- or long-acting basal insulin with rapid-acting prandial analogues.
Basal: NPH insulin (historically preferred; intermediate duration) or long-acting analogues (insulin detemir or insulin glargine, which provide steady, peakless coverage).
Prandial: Rapid-acting insulin analogues ( lispro or aspart ) injected 5 to 15 minutes before meals. They are superior to regular human insulin due to faster onset, shorter duration, and lower risk of delayed hypoglycemia.
Total Daily Dose (TDD) Calculation: Starting dose ranges from 0.7 to 1.0 units/kg of current pregnancy weight/day depending on gestational age (0.7 U/kg in 1st trimester; 0.8 U/kg at 18–26w; 0.9 U/kg at 26–36w; 1.0 U/kg at 36w to term). A standard split divides TDD into two-thirds in the morning (2/3 intermediate, 1/3 rapid) and one-third in the evening (split between rapid before dinner and intermediate at bedtime), or basal-bolus dosing (50% basal, 50% prandial divided among meals).
2. Metformin
Mechanism & Placental Transfer: Biguanide that decreases hepatic gluconeogenesis and increases peripheral glucose utilization. Metformin readily crosses the placenta , achieving umbilical cord blood concentrations equal to or higher than maternal levels.
Clinical Status: Acceptable second-line agent when a patient declines insulin, cannot safely store or inject insulin, or cannot afford it. Studies show higher rates of preterm birth and smaller infant size at birth, but lower maternal gestational weight gain and preeclampsia rates compared to insulin. Long-term pediatric metabolic outcomes remain under active investigation.
3. Glyburide
Mechanism & Placental Transfer: Second-generation sulfonylurea that stimulates pancreatic beta-cell insulin secretion. Crosses the placenta in significant concentrations.
Clinical Status: Associated with higher rates of macrosomia, neonatal hypoglycemia, and admission to the neonatal intensive care unit compared to both insulin and metformin. Consequently, glyburide is not recommended as a first-line agent.
Fetal Surveillance and Delivery Timing in GDM
A1GDM (Diet-Controlled): Routine antepartum fetal surveillance (nonstress tests [NST] or biophysical profiles [BPP]) is not indicated if blood glucose levels remain well-controlled, unless other obstetric risk factors (e.g., chronic hypertension, advanced maternal age, suspected fetal growth restriction) supervene. Delivery is recommended between 39 0/7 and 40 6/7 weeks gestation ; expectant management beyond 41 weeks is avoided.
A2GDM (Medication-Controlled): Antenatal fetal surveillance (twice-weekly NSTs or modified BPP) is initiated at 32 0/7 to 36 0/7 weeks gestation . Serial ultrasound biometry is performed every 3 to 4 weeks starting at 28 to 32 weeks to evaluate fetal abdominal circumference and estimated fetal weight (EFW). Planned delivery is recommended between 39 0/7 and 39 6/7 weeks gestation (or earlier, between 37 0/7 and 38 6/7 weeks, if glycemic control is persistently subtherapeutic or maternal/fetal vascular complications arise).
Cesarean Delivery for Suspected Macrosomia: When estimated fetal weight exceeds 4,500 grams in a diabetic pregnancy, the clinician must counsel the patient regarding the markedly elevated risk of shoulder dystocia, permanent brachial plexus injury, and maternal perineal trauma, offering planned elective cesarean delivery.